vs
Side-by-side financial comparison of CAMDEN NATIONAL CORP (CAC) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $64.3M, roughly 1.3× CAMDEN NATIONAL CORP). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 22.6%).
Camden National Bank is a commercial bank headquartered in Camden, Maine, operating as the principal subsidiary of Camden National Corporation, a publicly traded bank holding company. Founded in 1875, the bank became a direct, wholly owned subsidiary of the holding company following a corporate reorganization in 1984. Following the 2025 merger with Northway Financial, the combined institution has approximately $7.0 billion in assets.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
CAC vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $64.3M | $86.8M |
| Net Profit | $21.9M | — |
| Gross Margin | — | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 34.0% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $1.29 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $64.3M | — | ||
| Q4 25 | $68.1M | $86.8M | ||
| Q3 25 | $65.4M | $67.5M | ||
| Q2 25 | $62.3M | $60.0M | ||
| Q1 25 | $60.1M | $49.3M | ||
| Q4 24 | $47.6M | $73.7M | ||
| Q3 24 | $45.0M | $58.6M | ||
| Q2 24 | $42.8M | $31.1M |
| Q1 26 | $21.9M | — | ||
| Q4 25 | $22.6M | — | ||
| Q3 25 | $21.2M | $-91.3M | ||
| Q2 25 | $14.1M | $-111.7M | ||
| Q1 25 | $7.3M | $-116.2M | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | $13.1M | $-83.5M | ||
| Q2 24 | $12.0M | $-97.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | — | 43.0% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | — | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | 41.5% | -84.7% | ||
| Q3 25 | 40.5% | -140.7% | ||
| Q2 25 | 28.5% | -189.8% | ||
| Q1 25 | 10.3% | -245.8% | ||
| Q4 24 | 38.7% | -117.5% | ||
| Q3 24 | 35.2% | -152.1% | ||
| Q2 24 | 34.7% | -327.6% |
| Q1 26 | 34.0% | — | ||
| Q4 25 | 33.1% | — | ||
| Q3 25 | 32.4% | -135.3% | ||
| Q2 25 | 22.6% | -186.2% | ||
| Q1 25 | 12.2% | -235.5% | ||
| Q4 24 | 30.8% | — | ||
| Q3 24 | 29.1% | -142.7% | ||
| Q2 24 | 28.0% | -312.2% |
| Q1 26 | $1.29 | — | ||
| Q4 25 | $1.33 | — | ||
| Q3 25 | $1.25 | — | ||
| Q2 25 | $0.83 | $-0.33 | ||
| Q1 25 | $0.43 | $-0.36 | ||
| Q4 24 | $1.00 | $-0.24 | ||
| Q3 24 | $0.90 | $-0.28 | ||
| Q2 24 | $0.81 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $514.4M | — |
| Stockholders' EquityBook value | $710.0M | $698.6M |
| Total Assets | $7.0B | $913.2M |
| Debt / EquityLower = less leverage | 0.72× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | $514.4M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $710.0M | — | ||
| Q4 25 | $696.6M | $698.6M | ||
| Q3 25 | $676.4M | $702.3M | ||
| Q2 25 | $652.1M | $698.5M | ||
| Q1 25 | $640.1M | $767.9M | ||
| Q4 24 | $531.2M | $710.4M | ||
| Q3 24 | $529.9M | $773.5M | ||
| Q2 24 | $508.3M | $768.5M |
| Q1 26 | $7.0B | — | ||
| Q4 25 | $7.0B | $913.2M | ||
| Q3 25 | $7.0B | $904.9M | ||
| Q2 25 | $6.9B | $907.4M | ||
| Q1 25 | $7.0B | $966.7M | ||
| Q4 24 | $5.8B | $910.4M | ||
| Q3 24 | $5.7B | $991.1M | ||
| Q2 24 | $5.7B | $964.3M |
| Q1 26 | 0.72× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $63.9M | $-52.6M | ||
| Q3 25 | $36.1M | $-78.7M | ||
| Q2 25 | $6.0M | $-67.4M | ||
| Q1 25 | $1.0M | $-103.7M | ||
| Q4 24 | $60.9M | $-73.3M | ||
| Q3 24 | $-14.5M | $-59.0M | ||
| Q2 24 | $14.5M | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | $58.2M | $-61.9M | ||
| Q3 25 | $35.4M | $-89.5M | ||
| Q2 25 | $4.5M | $-74.9M | ||
| Q1 25 | $-727.0K | $-109.9M | ||
| Q4 24 | $55.4M | $-77.5M | ||
| Q3 24 | $-16.2M | $-61.3M | ||
| Q2 24 | $13.2M | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | 85.5% | -71.3% | ||
| Q3 25 | 54.1% | -132.7% | ||
| Q2 25 | 7.3% | -124.9% | ||
| Q1 25 | -1.2% | -222.8% | ||
| Q4 24 | 116.4% | -105.1% | ||
| Q3 24 | -36.0% | -104.6% | ||
| Q2 24 | 30.8% | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | 8.4% | 10.7% | ||
| Q3 25 | 1.1% | 16.1% | ||
| Q2 25 | 2.4% | 12.4% | ||
| Q1 25 | 2.9% | 12.6% | ||
| Q4 24 | 11.7% | 5.7% | ||
| Q3 24 | 3.8% | 3.9% | ||
| Q2 24 | 3.0% | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.83× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 0.43× | — | ||
| Q1 25 | 0.14× | — | ||
| Q4 24 | 4.15× | — | ||
| Q3 24 | -1.11× | — | ||
| Q2 24 | 1.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
